title: Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia.
abstract: OBJECTIVE
  To assess the extent of hyperenhancement in hypertrophic cardiomyopathy (HCM) patients with nonsustained ventricular tachycardia (NSVT) in comparison to patients without NSVT.
  
  
  METHODS
  In HCM patients, NSVT in Holter monitoring is a risk factor for sudden cardiac death; however, its positive predictive value is low. Varying risk of sudden death related to NSVT may be dependent on the heterogeneous extent of the arrhythmogenic substrate, which seems to be visible as hyperenhancement in gadolinium-enhanced magnetic resonance imaging (MRI).
  
  
  METHODS
  Hyperenhancement was assessed in 47 HCM patients (30 males and 17 females, mean age 42 +/- 12 years): 32 patients had NSVT, 15 patients had no NSVT. The extent of hyperenhancement was calculated by software and expressed as a mass.
  
  
  RESULTS
  In HCM patients with NSVT 97% had some extent of hyperenhancement on MRI, ranging from 1 to 76 g. The mean mass of hyperenhanced myocardium was 19 +/- 18 g (8.1 +/- 7.6% of total left ventricular mass). In HCM patients without NSVT, a significantly lower percentage of patients (60%) had hyperenhancement (P < 0.05). However, the amount of hyperenhanced myocardium was not significantly different (13 +/- 19 g, 6.3 +/- 9.1% of total left ventricular mass; P < 0.05).
  
  
  CONCLUSIONS
  Hyperenhancement was visible in almost all HCM patients with NSVT (97%) and in a significantly lower percentage of patients without NSVT (60%). Whether this finding explains the increased risk of sudden death in case of NSVT is not clear, since the extent of hyperenhancement was not significantly different between the two groups.
authors.affiliation: 2nd Department of Cardiology, Collegium Medicum Jagiellonian University, ul. Kopernika 17, Krakow 31-501, Poland. dimitrow@mp.pl
authors.forename: Paweł Petkow
authors.initials: PP
authors.lastname: Dimitrow
authors.forename: Piotr
authors.initials: P
authors.lastname: Klimeczek
authors.forename: Rozemarijn
authors.initials: R
authors.lastname: Vliegenthart
authors.forename: Mieczysław
authors.initials: M
authors.lastname: Pasowicz
authors.forename: Matthijs
authors.initials: M
authors.lastname: Oudkerk
authors.forename: Piotr
authors.initials: P
authors.lastname: Podolec
authors.forename: Wiesława
authors.initials: W
authors.lastname: Tracz
authors.forename: Jacek S
authors.initials: JS
authors.lastname: Dubiel
mesh_terms: D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D016022:Case-Control Studies; D003287:Contrast Media; D016757:Death, Sudden, Cardiac / Q000209:etiology* / Q000473:pathology; D015716:Electrocardiography, Ambulatory; D005260:Female; D005355:Fibrosis; D019786:Gadolinium DTPA; D006339:Heart Rate; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D019028:Magnetic Resonance Imaging, Cine; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D017180:Tachycardia, Ventricular / Q000150:complications / Q000473:pathology* / Q000503:physiopathology
chemical_list: D003287:Contrast Media; D019786:Gadolinium DTPA